All In Biotech

Drug Trial Radar · NCT06059547

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Sep 6, 2023

Primary completion

Oct 16, 2025

Study completion Jun 5, 2026

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical Cystectomy (RC)/Re-TURBT who cannot receive or refuse to receive cisplatin-based chemotherapy.

Conditions

  • Bladder Cancer
  • Adult Solid Tumor

Interventions

  • NivolumabDrug

    Biological, monoclonal antibody

  • Visugromab (CTL-002)Drug

    Biological, monoclonal antibody

  • PlaceboDrug

    Placebo (NaCl) for Visugromab (CTL-002)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response rateTime frame: min. 4 months
  2. Radiological response rate according RECISTTime frame: min. 4 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica

    Roma, Italy

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.